Cytomegalovirus Infection clinical trials

Explore recruiting cytomegalovirus infection clinical trials.

Recruiting cytomegalovirus infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cytomegalovirus Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Finland, Italy, Spain, France, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

LUCY-1 - Letermovir/valganciclovir combination versus valganciclovir monotherapy for treatment of cytomegalovirus (CMV) infections in kidney transplant recipients

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

PILOT ANTI-CMV CLINICAL TRIAL: PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN HLA-IDENTICAL FAMILIAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ADVANCED CELLULAR IMMUNOTHERAPY IN PATIENTS WITHOUT SPECIFIC PHARMACOLOGYCAL PROPHYLAXIS AVAILABLE

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CYMEVALIII - Prenatal treatment of congenital cytomegalovirus infection with letermovir randomized against valaciclovir (CYMEVAL) III

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparison of the efficacy and safety of valaciclovir in the prevention of transmission and treatment of intrauterine infection in pregnant women with primary cytomegalovirus infection depending on the used drug dose - the first Polish non-commercial non-inferiority clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney transplant patients - CYTOPREV

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cytomegalovirus Infection trials by city

Cytomegalovirus Infection in Toronto Cytomegalovirus Infection in Vancouver Cytomegalovirus Infection in Montreal Cytomegalovirus Infection in Calgary Cytomegalovirus Infection in Edmonton Cytomegalovirus Infection in Ottawa Cytomegalovirus Infection in Winnipeg Cytomegalovirus Infection in Quebec City Cytomegalovirus Infection in Hamilton Cytomegalovirus Infection in Kitchener Cytomegalovirus Infection in London Cytomegalovirus Infection in Halifax Cytomegalovirus Infection in New York Cytomegalovirus Infection in Los Angeles Cytomegalovirus Infection in Chicago Cytomegalovirus Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease